Design, Synthesis, and Biological Evaluation of 1-[(2-Benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with an Improved Drug Resistance Profile
- 27 January 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (5), 2242-2250
- https://doi.org/10.1021/jm201506e
Abstract
Because the emergence of drug-resistant mutants has limited the efficacy of non-nucleoside reverse transcriptase inhibitors (NNRTIs), it is essential to develop new antivirals with better drug resistance and pharmacokinetic profiles. Here we designed and synthesized a series of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils, the HEPT analogues, and evaluated their biological activity using nevirapine and 18 (TNK-651) as reference compounds. Most of these compounds, especially 6b, 7b, 9b, 11b, and 7c, exhibited highly potent anti-HIV-1 activity against both wild-type and NNRTI-resistant HIV-1 strains. Compound 7b, which had the highest selectivity index (SI = 38 215), is more potent than nevirapine and 18. These results suggest that the introduction of a halogen at the C-5 position may contribute to the effectiveness of these compounds against RTI-resistant variants. In addition, meta substituents on the C-6 aromatic moiety could significantly enhance activity against NNRTI-resistant HIV-1 strains. These compounds can be further developed as next-generation NNRTIs with an improved antiviral efficacy and drug-resistance profile.Keywords
This publication has 38 references indexed in Scilit:
- Genotypic and Phenotypic Cross-Drug Resistance of Harboring Drug-Resistant HIV Type 1 Subtype B′ Strains from Former Blood Donors in Central Chinese ProvincesAIDS Research and Human Retroviruses, 2010
- The design and synthesis of N-1-alkylated-5-aminoaryalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitorsBioorganic & Medicinal Chemistry, 2007
- HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistanceTrends in Pharmacological Sciences, 2005
- TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimenAIDS, 2003
- A 3D QSAR Study of a Series of HEPT Analogues: The Influence of Conformational Mobility on HIV-1 Reverse Transcriptase InhibitionJournal of Medicinal Chemistry, 1997
- Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitorsNature Structural & Molecular Biology, 1995
- High resolution structures of HIV-1 RT from four RT–inhibitor complexesNature Structural & Molecular Biology, 1995
- Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitorsNature Structural & Molecular Biology, 1995
- Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolutionStructure, 1995
- Synthesis of 4-(1,2,4-triazol-1-yl)-pyrimidin-2(1H)-one ribonucleotide and its application in synthesis of oligoribonucleotidesThe Journal of Organic Chemistry, 1982